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Structured Abstract 9 
Background: The chemical composition of Layered Double Hydroxides (LDHs) affects their 10 
structure and properties. The method of ibuprofen (IBU) intercalation into LDHs may modify its 11 
release, reduce adverse effects, and decrease the required dosing frequency. 12 
Methodology: This study investigates the effects of four different LDHs; MgAl-LDH, MgFe-LDH, 13 
NiAl-LDH and NiFe-LDH on in vitro release of IBU intercalated by co-precipitation and anionic-14 
exchange. 15 
Results: MgAl-LDH was the most crystalline and substitution of either cation decreased LDH order. 16 
FT-IR spectra and pXRD confirmed the intercalation of IBU within the lamellar structure of MgAl-17 
LDH and MgFe-LDH. Intercalation of IBU by anion-exchange resulted in slower, partial, drug release 18 
compared co-precipitation. 19 
Conclusions: The chemical composition of LDHs affects their crystallinity, IBU intercalation and 20 
subsequent release.  21 
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1. Introduction  30 
 Layered double hydroxides (LDHs) are inorganic lamellar solids often referred to as 31 
hydrotalcite-like minerals [1]. They are sometimes referred to as anionic clays due to their physical 32 
and chemical similarities with clay mineral [1] but LDHs have anions between octahedral layers [2], 33 
whereas clay minerals have cations between octahedral-tetrahedral layers [1]. 34 
 The layers of LDHs are assembled from octahedral sheets of divalent and trivalent metal 35 
hydroxides bound together through edge-sharing. The charge imbalance across the sheet, 36 
attributed to the di- and trivalent metal cations, results in a net positive charge [2]. LDH sheets can 37 
be stacked on top of each other with anions and water molecules between the sheets to 38 
counterbalance the positive charge. These interlayer anions are commonly carbonate, halides, 39 
nitrates or sulphates [2]. Water molecules and other anionic species can also reside in the 40 
interlayer space from the synthesis of the LDH sheets, or through incorporation methods such as 41 
anionic-exchange [1]. As expected, the interlayer distance depends on the size, charge and 42 
arrangement of the anionic species within the interlayer space [1]. 43 
The chemical composition of LDHs is generally described as [MII1-xMIIIx(OH)2][Xq-x/q•nH2O], 44 
where MII is the divalent cation such as Mg2+, Mn2+, Fe2+, Co2+, Ni2+ and MIII is the trivalent cation 45 
such as Al3+, Mn3+, Fe3+, Co3+, Ni3+ [1]. These metal cations must be of similar ionic radius to 46 
Mg2+ions to be able to fit in the brucite-like (Mg(OH)2) layers [1]. Additionally, it has been 47 
suggested that the charge density (MIII/(MII+MIII)) which relates to the anionic exchange capacity 48 
must be between 0.2 and 0.33, with the MII/MIII ratio being between 2 and 4.37 to get a pure LDHs 49 
structure [2]. The chemical variation of LDHs is diverse due to the possible ratios and combinations 50 
of divalent and trivalent cations, in addition to the choice of anions that can be incorporated 51 
between the layers [3]. Moreover, preparations of LDHs containing quaternary and monovalent 52 
cations have also been reported [4,5]. 53 
 LDHs can act as drug carriers due to their positively charged layers and interlayer anions that 54 
can be exchanged for negatively charged drug compounds for storage and subsequent release in a 55 
controlled manner [6,7]. Current developments in drug-delivery systems strive to optimise drug-56 
release by means of maintaining a therapeutic concentration of the drug at the targeted site for an 57 
extended period of time, thus prolonging the therapeutic effects, reducing the dosing frequency 58 
and minimising dose-related adverse effects [3]. Recent years have seen a growing interest in the 59 
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pharmaceutical applications of LDHs as controlled drug delivery systems [4,8]. LDH chemical 60 
composition affects the layer structure and properties, which affects the intercalation and release 61 
of drug molecules [9]. Therefore, it is possible to optimise the chemical composition of LDHs to 62 
design controlled release drug nanocarriers that are also biocompatible in vivo [10,11]. 63 
Furthermore, the application of LDH materials in the biomedical field expands beyond their 64 
nanoparticle drug carrying properties and includes, amongst other applications, the use of LDHs in 65 
biomaterials for tissue engineering [12] and applications as biosensors [13], as well as formulation 66 
into hybrid polymer containing nanocomposite hydrogels [14], films [15] and beads [16].  67 
 The most common intercalation methods described are co-precipitation (co) and anionic-68 
exchange (ex) [4] but can also be achieved through reconstruction, hydrothermal precipitation and 69 
transformation methods [4,17,18]. These intercalation methods produce different LDH-drug 70 
composites in terms of their structure, bonding, purity and amount of intercalated drug [19], which 71 
consequently influence drug release rate and characteristics [20].  72 
 LDHs offer many advantages as drug carriers due to a high adsorptive capacity, low toxicity [1], 73 
ability to improve drug stability [21], and being easy and inexpensive to prepare. In recent years, 74 
LDHs have been used to successfully intercalate many drugs and biomolecules including anti-75 
inflammatory drugs [3,4], antihypertensive drugs [22], antimicrobials [23], anticancer drugs [24], 76 
and DNA fragments [25].  77 
 Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of molecules indicated for the 78 
treatment of pain and inflammation [26]. However, these drugs are limited by their low water 79 
solubility [27] which can restrict their dissolution and absorption in the body. A study on naproxen 80 
and flurbiprofen showed a substantial increase in water solubility and improved drug 81 
bioavailability when intercalated within MgAl-LDH [19]. Similarly, Capsoni et al. found that co-82 
precipitating carprofen with Zn2Al-LDH significantly increased the drugs solubility potentially 83 
improving subsequent absorption [28]. The solubility of NSAIDs are also increased when LDHs 84 
were included as additives, but to a lesser extent than when intercalated within the layers [29]. 85 
Furthermore, the LDH layers can also act as a barrier and provide gastrointestinal protection 86 
against the adverse effects of NSAIDs [30]. 87 
 Several studies also demonstrated that LDHs can modify and prolong the release of the 88 
intercalated NSAIDs [3,4]. For example, Ambrogi et al. intercalated ibuprofen (IBU) into MgAl-LDH 89 
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and observed slower in vitro release compared to the commercial formulation [31]. Li et al. 90 
revealed that the dissolution of fenbufen was slower when intercalated by co-precipitation in 91 
MgAl-LDH and MgLi-LDH [32]. However, the MgAl-LDH was concluded to be the more effective 92 
delivery system as its release rate was significantly slower. The chemical composition of LDHs affect 93 
drug intercalation. For example, del Arco et al. showed that fenbufen intercalated successfully in 94 
MgAl-LDH via co-precipitation, anionic exchange, and reconstruction but it was only intercalated 95 
into MgAlFe-LDH by co-precipitation and anionic-exchange [3]. Subsequently, MgAl-LDH released 96 
its intercalated drug fully while MgAlFe-LDH released 93% of its intercalated drug at a slower rate 97 
[29].  98 
 Another study revealed that the release rate of naproxen decreased when the charge density 99 
of the LDHs delivery system increased [33]. Williams and O’Hare suggested that the release of 100 
NSAIDs from LDHs is affected by the pH of the release medium, demonstrating a slower release at 101 
pH 7 than at pH 4 due to acidity causing hydrolysis of the LDH sheets [9]. Additionally, the impact 102 
of interlayer space size on drug loading and subsequent release has been demonstrated by 103 
Djaballah et al. [5] who demonstrated suitability of the very short interlayer space in ZnTi-LDH to 104 
deliver low-dose therapy of intercalated IBU.   105 
 These studies show that the intercalation of NSAIDs into LDHs for a modified release system 106 
depends on multiple factors, including the chemical composition and charge density of the LDHs, 107 
the intercalation method and the pH of the release medium. These variables collectively influence 108 
the LDH structure and orientation of the drug molecules within the interlayer space, which will 109 
consequently affect the rate and amount of drug released. Williams and O’Hare suggest it is 110 
possible to optimise these factors to obtain an optimal modified release formulation of the drug, 111 
although these have not yet been fully investigated [9]. Current interests include further improving 112 
the drug delivery potential of LDHs and research into this had included surface coating the drug 113 
loaded LDH nanoparticles with mesoporous silica [34].  114 
 The aim of this work was to investigate and characterise the effects of four different metal 115 
compositions of LDH sheets (MgAl-LDH, MgFe-LDH, NiAl-LDH and NiFe-LDH) on the intercalation 116 
and in vitro drug-release of IBU using two different intercalation methods: co-precipitation and 117 
anionic-exchange.  118 
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2. Materials and Methods 119 
2.1 LDH-IBU composite preparation 120 
2.1.1. Co-precipitation of LDH-IBU composites  121 
 Co-precipitation (co) was used to prepare the following four metal compositions of LDH-IBU 122 
composites: MgAl-LDH-IBU(co), MgFe-LDH-IBU(co), NiAl-LDH-IBU(co), and NiFe-LDH-IBU(co).  123 
This involved preparing the relevant metal salts solution (molar ratio metal ion2+/metal ion3+ 124 
=1:2) [31]. Firstly, 0.025 mol of divalent metal chloride salt (MgCl2 or NiCl2) and 0.0125 mol of 125 
trivalent metal chloride salt (AlCl3 or FeCl3) were dissolved in 50 mL of deionised water. Secondly, a 126 
caustic solution of the drug was prepared by dissolving 0.0125 mol of IBU into a solution 127 
containing 5 M NaOH (3 mL) and deionised water (50 mL). 128 
 The metal salts solution was added dropwise from a burette into a stirring caustic solution of 129 
IBU. Additions of 5 M NaOH solution were made as necessary to maintain the mixture at pH 9. The 130 
exact volume of 5 M NaOH (8 – 14mL) solution added was recorded to establish the final volume 131 
of the resultant mixture. Once all of the metal salts solution was added, the viscous resultant 132 
mixture was left to stir for one hour following which it was centrifuged at 25000 rpm for 20 133 
minutes and the pellets were dried. After drying, the solid products were grounded into fine 134 
particles using a mortar and pestle, and the weights of the solids were recorded and the yields 135 
calculated according to the following equation: 136 
𝑌𝑖𝑒𝑙𝑑 (%) =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝐿𝐷𝐻 𝑜𝑏𝑡𝑎𝑖𝑛𝑒𝑑 (𝑔)
 𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑚𝑒𝑡𝑎𝑙 𝑠𝑎𝑙𝑡𝑠 𝑎𝑛𝑑 𝐼𝐵𝑈 𝑢𝑠𝑒𝑑 (𝑔)
𝑥100 137 
The supernatant was kept to assay the amount of IBU not intercalated, as detailed in section 138 
2.3 below. 139 
 140 
2.1.2 Anionic-exchange of LDHs with IBU 141 
 The anionic exchange (ex) method was used to prepare the following four metal compositions 142 
of LDH-IBU composites: MgAl-LDH-IBU(ex), MgFe-LDH-IBU(ex), NiAl-LDH-IBU(ex) and NiFe-LDH-143 
IBU(ex).  144 
This involved a two-step process; the first step involved the co-precipitation of MgAl-LDH, 145 
MgFe-LDH, NiAl-LDH and NiFe-LDH exactly as detailed above, but excluding the IBU in the caustic 146 
solution. The second step involved equilibrating 1 g of the LDHs with 2 g of IBU dissolved in a 147 
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solution containing 5 M NaOH (10 mL) and deionised water (74 mL). This mixture was covered with 148 
foil paper, heated to 60 °C [31] and stirred vigorously on a hotplate stirrer for 3 hours. After 3 149 
hours, the mixture was left to cool before centrifuging at 25000 rpm for 20 minutes. After 150 
centrifugation, the pellets were dried the solid products were grounded into fine particles using a 151 
mortar and pestle, and the weights of the solids were recorded. The supernatant (3 mL) was kept 152 
to assay the amount of IBU not intercalated, as detailed in section 2.3. 153 
 154 
2.1.3 Preparation of the physical mixes 155 
 Different metal salts and IBU were mixed together in a mortar and pestle to prepare physical 156 
mixes equivalent to each of the LDHs synthesised. The amounts used reflected the 2:1 ratio of the 157 
divalent and trivalent metal salts. Additionally, the amount of IBU used was equivalent to the 158 
amount of IBU determined from the co-precipitated LDH-IBU composites (section 2.3). 159 
 160 
2.2 Characterisation of LDH-IBU composite 161 
 The composites were analysed on a Perkin Elmer Spectrum 1000 Fourier-Transform Infrared 162 
(FT-IR) Spectrophotometer with a Pike Miracle ATR attachment in the range of 4000 to 600 cm-1. 163 
The power X-ray diffractograms (pXRD) of the composites were collected on a Rigaku Mini-Flex X-164 
ray diffractometer using Cu Kα radiation of wavelength 1.54 Å in the scan range 2θ: 3° to 30°. 165 
The LDHs and LDH-IBU composites were analysed using FT-IR spectroscopy and pXRD. The 166 
physical mixes were analysed using FT-IR spectroscopy only. 167 
 168 
2.3 Determination of amount of IBU intercalated 169 
 All UV analysis was completed on the Thermo Spectronic Genesys 10 UV-Visible 170 
Spectrophotometer at wavelength 265 nm.  171 
 172 
2.3.1 Back-exchange method (carbonate-ion exchange) 173 
 The amount of IBU intercalated into each LDH-IBU composite was determined by carbonate-174 
ion back-exchange. This involved exchanging higher affinity carbonate ions with intercalated IBU, 175 
thus releasing the drug out of the LDHs for quantifying with UV spectroscopy.  176 
0.005 mol sodium carbonate decahydrate (1.4307 g) was dissolved in phosphate buffered 177 
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saline (50 mL, pH 7.4). This mixture was heated to 80 °C before adding 500 mg of LDH-IBU. Then, 178 
the mixture was sealed with foil, stirred and maintained at 80 °C for 4 hours using a magnetic 179 
hotplate stirrer. When cooled to room temperature, 3 mL of the mixture was pipetted out, 180 
centrifuged and its supernatant was analysed in a quartz cuvette under UV spectroscopy at 265 nm 181 
to determine the mass of IBU released from 500 mg of LDH-IBU. This was then used to calculate 182 
the amount of IBU loaded into the various composites using the following equation: 183 
𝐼𝐵𝑈 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (𝑚𝑔/𝑔 𝐿𝐷𝐻) =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝐼𝐵𝑈 𝑑𝑒𝑡𝑒𝑟𝑚𝑖𝑛𝑒𝑑 𝑏𝑦 𝑏𝑎𝑐𝑘 − 𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒 (𝑚𝑔)
 𝑚𝑎𝑠𝑠 𝑜𝑓 𝐿𝐷𝐻 𝑢𝑠𝑒𝑑 𝑖𝑛 𝑏𝑎𝑐𝑘 − 𝑒𝑎𝑐ℎ𝑎𝑛𝑔𝑒(𝑔)
 184 
 185 
2.3.2 IBU intercalation efficiency 186 
 The amount of IBU not intercalated into the various composites was determined by 187 
measuring the amount of IBU remaining in the supernatant of the intercalation mixture after 188 
centrifugation. The supernatant was analysed in a quartz cuvette under UV spectroscopy at 265 189 
nm to determine the mass of IBU not intercalated. This was deducted from the initial mass of IBU 190 
added and used to calculate the percentage intercalation efficiency using the following equation:  191 
𝐼𝐵𝑈 𝑖𝑛𝑡𝑟𝑐𝑎𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%)192 
=
𝑚𝑎𝑠𝑠 𝑜𝑓 𝐼𝐵𝑈 𝑢𝑠𝑒𝑑 (𝑚𝑔) − 𝑚𝑎𝑠𝑠 𝐼𝐵𝑈 𝑛𝑜𝑡 𝑖𝑛𝑡𝑒𝑟𝑐𝑎𝑙𝑎𝑡𝑒𝑑 (𝑚𝑔)
 𝑚𝑎𝑠𝑠 𝑜𝑓 𝐼𝐵𝑈 𝑢𝑠𝑒𝑑 (𝑚𝑔)
𝑥100 193 
 194 
2.4 In vitro drug release 195 
 A sample of each physical mix and co-precipitated and anion exchanged LDH-IBU composite 196 
(230 mg) was suspended in separate round-bottom flasks containing phosphate buffer saline (PBS, 197 
200 mL, pH 7.4) under constant stirring, in an incubator at a constant physiological temperature 198 
(37 ± 5 °C). The mass of the sample suspended was equivalent to approximately 100 mg of IBU, as 199 
estimated from the preliminary back-exchange. This mass/volume ratio was chosen to correspond 200 
to the sink conditions, based on the solubility of IBU at pH 7.4 [31]. 201 
Once, the samples were suspended, aliquots (1 mL) of dissolution medium were taken at 5 202 
minutes interval up to one hour. The aliquots were then centrifuged and their supernatant were 203 
analysed under UV spectroscopy at 265 nm. One millilitre of PBS was replaced after each aliquot 204 
sample was removed to maintain sink conditions. The dissolution tests were repeated and the 205 
average absorbance values were used to determine the concentration of IBU released.  206 
The amount of IBU released was calculated as a percentage over the total amount of IBU in 207 
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230 mg of the physical mix, or the total amount of intercalated IBU in 230 mg of LDH-IBU 208 
composite. 209 
  210 
3. Results and Discussion 211 
3.1 Intercalation of IBU in LDHs by co-precipitation and anionic-exchange 212 
 During the co-precipitation of LDHs a pH of 9 was maintained. This alkaline environment was 213 
required to create a supersaturated conditions for the hydroxide ions to displace the metal salts 214 
and form a precipitate [35]. Precipitation occurred when the NaOH solution was added into 215 
mixtures of metals salts with and without IBU. However, a larger addition of NaOH solution was 216 
generally required to maintain pH 9 during the co-precipitation of LDHs with IBU due to the acidic 217 
nature of IBU [20]. 218 
Table 1. Yield of LDHs prepared without ibuprofen (IBU) and via co-
precipitation with IBU. 
LDH composite Yield (%) with no IBU Yield (%) co-
precipitated with IBU 
MgAl-LDH 85 79 
MgFe-LDH 71 65 
NiAl-LDH 70 62 
NiFe-LDH 77 60 
 219 
 Co-precipitation of LDHs with IBU produced a lower yield than without IBU (table 1). This 220 
indicates that LDHs form more easily with chloride anions than IBU anions, which suggests that the 221 
presence of IBU disrupts the formation of LDH layers due to its relatively larger size and hydrophobic 222 
nature. Bulky anions are capable of moving the layers out of alignment as a consequence of the 223 
turbostratic effect [2], thus less layers can be assembled during co-precipitation. Additionally, 224 
MgAl-LDH and co-precipitated MgAl-LDH-IBU had a higher yield compared to the other co-225 
precipitated composites. This indicates that these metal ions are more efficient in forming LDHs, 226 
which was expected as MgAl-LDHs have a similar composition to the natural mineral hydrotalcite 227 
[4]. 228 
 The co-precipitation process resulted in considerably higher IBU intercalation efficiencies than 229 
anionic-exchange (table 2). This is likely due to the varying intercalation mechanism, as explained 230 
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below with the difference in interlayer spacing. Similar findings have been reported by other 231 
groups, Djebbi et al. describe a lower adoption of berberine chloride into MgAl-LDH prepared by 232 
ion-exchange compared to equivalent co-precipitation methods [36].  233 
  234 
Table 2. Ibuprofen (IBU) intercalated 
 
co-precipitated (co)  anion-exchanged (ex) 
MgAl-
LDH-
IBU(co) 
MgFe-
LDH-
IBU(co) 
NiAl-
LDH-
IBU(co) 
NiFe-
LDH-
IBU(co) 
MgAl-
LDH-
IBU(ex) 
MgFe-
LDH-
IBU(ex) 
NiAl-
LDH-
IBU(ex) 
NiFe-
LDH-
IBU(ex) 
IBU 
intercalation 
efficiency (%) 
90.31 87.98 76.36 58.14 29.50 27.50 25.50 23.00 
 
IBU loading 
(mg/g LDH 
composite) 
420 490 396 314 368 342 296 252 
 In both methods, MgAl-LDH and MgFe-LDH intercalated more IBU than NiAl-LDH and NiFe-235 
LDH, which may be due to the increased order and crystallinity of MgAl-LDHs and MgFe-LDH 236 
compared to Ni containing LDH (see section 3.4). Ambrogi et al. (2001) reported to have achieved 237 
an IBU content of 50% by anionic exchange. MgAl-LDH was also reported to have intercalated 238 
fenbufen with a drug content of 51% when co-precipitated at pH 8, and 61% when precipitated at 239 
pH 13 [32]. This indicates that more drug molecules are intercalated at higher basicity, as the layers 240 
are more regular [32].  241 
 The IBU loading in the various composites (table 2) was deduced from the amount of IBU 242 
back-exchanged. In both types of composite materials (co-precipitated and ion exchanged) there 243 
was residual drug remaining on the LDHs that was not released during the back-exchange. 244 
However it is notable that IBU was relinquished from the anion-exchange prepared composites 245 
more readily, which suggests a stronger adsorption of IBU in the co-precipitated LDH composites. 246 
 247 
3.3 Characterisation of LDHs and physical mixes with FT-IR spectroscopy 248 
The FT-IR spectrum of IBU (figure 1e) consists of the characteristic C=O stretching vibrations 249 
at-1 due to the free carboxylic acid group, the C-H alkyl stretching at 2954-2868 cm-1 due to the 250 
aliphatic C-H groups [37], and the skeletal stretching vibrations between 1507-1418 cm-1 due to 251 
the C-C bonds in the aromatic ring [38]. These characteristic absorptions were also observed in the 252 
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physical mixes (figure 1d), suggesting that simply mixing IBU with the metal salts or LDHs does not 253 
result in intercalation. The FT-IR spectra of LDHs (figure 1a) display weak peaks at 1393-1357 cm-1 254 
indicating the presence of carbonate [3] and implies that carbonate anions were adsorbed onto 255 
the LDHs from the atmosphere and dispersion media due to their strong affinity [2]. 256 
 257 
 258 
Figure 1. FT-IR spectra of (a) the MgAl-LDH synthesised, (b) the co-precipitated MgAl-LDH-IBU, (c) 259 
the anion-exchanged MgAl-LDH-IBU, (d) a physical mix of MgCl2, AlCl3 and IBU and (e) IBU 260 
 261 
The aliphatic C-H stretching was present on the spectra of the physical mix sample and LDH-262 
IBU composites (figures 1b, c and d), but not of the LDHs without IBU (figure 1a). This establishes 263 
the presence of IBU in the physical mixes and LDH-IBU composites. The LDHs and LDH-IBU contain 264 
OH groups as shown by the broad FT-IR peak between 3400 and 3335 cm-1 relating to the hydroxyl 265 
groups within the LDH layers, and to the interlayer and adsorbed water [39]. The bending modes 266 
of OH bonds are only seen on the spectra of LDHs at 1634-1629 cm-1, as there are no IBU 267 
molecules to obscure it. The broadening of the OH stretching peak indicates that OH groups are 268 
hydrogen bonded [38].  269 
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The FT-IR absorption due to the free acid group of IBU is no longer visible on the spectra of 270 
LDH-IBU composites, confirming immobilisation of IBU onto the surface of LDHs. FT-IR absorption 271 
modes due to the asymmetric and symmetric stretching of the carboxylate anion group (COO-) are 272 
seen at 1556-1528 cm-1 and 1408-1360 cm-1, respectively (table 3). This implies that the negatively-273 
charged carboxyl group of IBU interacts with the positively charged layers of the LDHs. Similar 274 
changes in FT-IR spectra were reported with the intercalation of fenbufen [32] and indomethacin 275 
[37,40] into MgAl-LDH. Conversely, it was observed by del Arco et al. that this change did not occur 276 
with the intercalation of meclofenamic acid into MgAl-LDH because its sodium salt was used [3]. 277 
The FT-IR spectra of the LDH-IBU composites were similar (figure 2), which suggests that IBU 278 
interacts with these LDHs in the same manner regardless of intercalation method or LDH 279 
composition. The carbonyl stretching from IBU disappears in both the LDH-IBU composites and the 280 
COO- peaks occur at similar wavelengths. In addition, the FT-IR absorbance modes for the LDHs 281 
remained in their original positions, indicating the structure of the LDHs remained unchanged 282 
during and after the intercalation of IBU. 283 
 284 
 285 
 286 
Table 3. Absorption peaks of interest on the FT-IR spectra of ibuprofen (IBU), 
co-precipitated (co) LDH-IBU and anion-exchanged (ex) LDH-IBU composites. 
  
  
FT-IR absorption peaks (cm-1) 
ν(C=O) νas(COO-) νs(COO-) 
IBU 1709, s, sh - - 
MgAl-LDH-IB(co) - 1548, s, sh 1396,s, sh 
MgFe-LDH-IBU(co) - 1552, s, sh 1408, s, sh 
NiAl-LDH-IBU(co) - 1546, s, sh 1397, s, sh 
NiFe-LDH-IBU(co) - 1548, s, sh 1395, s, sh 
MgAl-LDH-IBU(ex) - 1548, m, sh 1362, s, sh 
MgFe-LDH-IBU(ex) - 1556, m, sh 1361, s, sh 
NiAl-LDH-IBU(ex) - 1542, m, sh 1363, s, sh 
NiFe-LDH-IBU(ex) - 1538, m, sh 1360, s, sh 
s = strong, m = medium, sh = sharp, νs = symmetrical stretching, νas= asymmetrical 
stretching 
 287 
 288 
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 289 
Figure 2. FT-IR spectra of co-precipitated (co) NiAl-LDH-IBU(co) (red), anion-exchanged (ex) NiAl-290 
LDH-IBU(ex) (blue) and ibuprofen (IBU) (black). 291 
 292 
3.4 Characterisation of LDHs with pXRD 293 
 MgAl-LDH was the most crystalline structure, followed by MgFe-LDH, NiAl-LDH and NiFe-LDH 294 
in descending order of crystallinity, with the latter two materials showing no observed diffraction 295 
at around 11 deg. 2θ (figure 3). This implies that the two Mg-containing materials are laminar 296 
crystalline LDH structures and whereas the two Ni-containing materials have formed amorphous 297 
metal oxides. This is due to the charge to size ratio of the metal ions which affects the layer charge 298 
density [41], and therefore influences the stacking of the layers. These data suggest the 299 
combination of magnesium and aluminium cations produce superior layer charge density than the 300 
other metal combinations. This finding is also supported by the existence of the only natural LDH, 301 
hydrotalcite, which consists of magnesium and aluminium ions [41]. The high crystallinity of MgAl-302 
LDH would also explain its high yield compared to the other LDHs (table 1). 303 
 304 
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305 
Figure 3. Diffractograms of synthesised LDHs (a, green) MgAl-LDH, (b, red) MgFe-LDH, (c, blue) 306 
NiAl-LDH, and (d, black) NiFe-LDH 307 
 308 
The method of synthesis affects the crystallinity of the LDHs, and consequently the orientation 309 
of IBU within the interlayer space. MgAl-LDH has a d003 value of 0.778 nm (table 4) which 310 
represents the size of one cationic layer and the interlayer space and is consistent with other LDHs 311 
reported in the literature [31,42]. Upon intercalation of IBU by co-precipitation and anionic 312 
exchange, the d003 value increased by 1.627 nm and 1.564 nm, respectively, demonstrating 313 
placement of IBU within the interlamellar space. This increase in interlayer space is similar to that 314 
seen with other organic anions of a similar size to IBU, such as fenbufen [32] and indomethacin 315 
[40] . 316 
 317 
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Table 4. Characteristics of peak d003 on the diffractograms of the LDHs, co-precipitated LDH-
IBU composites and anionic-exchanged LDH-IBU composites. 
LDHs composite d003 (nm) for LDH  
d003 (nm) for LDHs co-
precipitated with IBU 
d003 (nm) for LDHs 
anion-exchanged with 
IBU 
MgAl-LDH 0.778 2.405 2.342 
MgFe-LDH 0.796 2.425 0.796 
NiAl-LDH No diffraction  2.425 No diffraction 
NiFe-LDH No diffraction No diffraction No diffraction 
 318 
  Additionally, the increase in d-values for MgAl-LDHs containing IBU suggest that IBU formed 319 
a tilted bilayer between the layers [41], with its carboxylate groups interacting with the cationic 320 
surface and its primary axes perpendicular to the layers [32]. This arrangement has also been 321 
reported with the co-precipitation of ketoprofen and MgAl-LDH, which produced a similar 322 
expansion of the interlayer spacing by 1.72 nm [38].  323 
 The orientation of IBU occupies less interlayer space when intercalated via anionic-exchange 324 
than co-precipitation, as evident by the difference in expansion of interlayer space (table 4). This is 325 
likely because the co-precipitation allows the formation of hydroxides layers around IBU molecules, 326 
which would therefore encapsulate more anions, and widen the initial interlayer space. However, 327 
anionic-exchange intercalates IBU into LDHs that already contains small chloride anions in the 328 
interlayer space, which can inhibit absorption, hence reduced yield, and expansion of the 329 
interlayer space. 330 
 After intercalation of IBU via anion exchange into MgAl-LDH, the d003 reflection became more 331 
intense and sharper (diffractograms not shown). This suggests that the MgAl-LDH layered structure 332 
became more ordered after intercalation. The d003 reflection of co-precipitated MgAl-LDH-IBU 333 
composite is less intense than that of the MgAL-LDH and anionic exchanged MgAl-LDH-IBU 334 
equivalents, suggesting that co-precipitation produces LDH-IBU composites that are less ordered. 335 
This implies that IBU disrupts the stacking of the cationic layers during co-precipitation, which does 336 
not occur with anionic-exchange process as the LDH layers are already formed and associated 337 
before the intercalation of IBU. Huang el al. report an improved crystal structure when IBU-LDH 338 
materials are prepared by the hydrothermal precipitation method compared to the traditional co-339 
precipitation method also applied in this study [43] implying that harsher conditions are required 340 
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to overcome the issue of IBU hindering the formation of ordered layers. 341 
 MgFe-LDH exhibit basal reflections that are very broad, asymmetrical and have a low intensity 342 
(figure 3b) and represents a poorly crystalline structure with minimal layers [38]. The interlayer 343 
spacing is found to be 0.796 nm, which is the same value for MgFe-LDH reported by Gasser [44]. 344 
Magnesium and iron cations are not as efficient at forming structured LDHs as magnesium and 345 
aluminium cations under the same synthesis conditions. This is shown by the weaker reflections 346 
compared to MgAl-LDH, which is likely due to iron cations being larger than aluminium cations 347 
[45], which could create distortions within the cationic LDH layers [41].  348 
 Similarly, on intercalation of IBU into MgFe-LDH by co-precipitation, the interlayer space 349 
increased by 1.629 nm. This confirms the successful intercalation of IBU by co-precipitation, as the 350 
interlayer space expanded by the same distance as with the intercalation of IBU in MgAl-LDH. It 351 
also suggests that MgFe-LDH-IBU has the same bilayer arrangement of IBU as MgAl-LDH-IBU. 352 
Again, the reflections of MgFe-LDH-IBU(co) are less intense than MgAl-LDH-IBU(co) due to the 353 
distortion caused by the larger aluminium cations.  354 
 On the contrary, the intercalation of IBU into MgFe-LDH by anionic-exchange was 355 
unsuccessful, as the d003 value remained the same. This could be due to the irregular structure of 356 
the MgFe-LDH making it challenging for IBU to intercalate. Although, IBU did not intercalate into 357 
MgFe-LDH, its FT-IR spectra indicate that IBU still formed bonds with the LDH, meaning IBU was 358 
adsorbed onto the outer surfaces of the LDH particles. 359 
 The diffractograms of NiAl-LDH and NiFe-LDH do not exhibit any diffractions around 11 deg. 360 
2θ, thus an ordered layered structure was not formed. Nickel cations have a smaller ionic radius 361 
than magnesium cations [45], which increases its charge density and makes them more strongly 362 
bound to chloride anions; requiring more vigorous method to successfully synthesise nickel 363 
containing LDHs [46,47]. NiAl-LDH and NiFe-LDH have previously successfully been prepared using 364 
the co-precipitation method however the intercalation anion was carbonate [48,49] suggesting 365 
that chloride anions are not conducive to LDH formation for nickel containing materials. 366 
 As a lamellar structure was not formed, the intercalation of IBU by anionic-exchange was 367 
unsuccessful for both NiAl-LDH and NiFe-LDH, as evident from the absence of reflections in these 368 
diffractograms. While the intercalation of IBU into NiFe-LDH by co-precipitation was also 369 
unsuccessful, the pXRD analysis suggests that NiAl-LDH was able to intercalate IBU by co-370 
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precipitation as it had an interlayer space of 2.425 nm. This value is similar to the other IBU co-371 
precipitated LDHs in this study (MgAl-LDH-IBU and MgFe-LDH-IBU), which suggest that a bilayer of 372 
IBU had formed. In turn, this suggests IBU anions help the formation of the layered structure, 373 
which could not be formed with chloride anions alone. 374 
 375 
3.5 In vitro drug release  376 
The IBU release profiles in phosphate buffer saline (pH 7.4) from co-precipitated and ion-377 
exchanged LDH-IBU was performed on the five LDHs showing d003 reflections on their 378 
diffractograms (figure 4). The IBU release profile differed for each LDH-IBU composite tested 379 
showing that differences in LDH chemical composition and IBU intercalation method also affected 380 
the final drug release behaviour. The physical mixes of the parent LDHs (MgAl-LDH, MgFe-LDH and 381 
NiAl-LDH) and IBU did not show release profiles (data not shown) as all the IBU present in the mix 382 
had dissolved once suspended in the phosphate buffer saline. 383 
 384 
 385 
Figure 4. Drug release profiles of ibuprofen (IBU) from LDH-IBU composites of co-precipitated (co) 386 
MgAl-LDH-IBU(co) (dark blue diamonds), MgFe-LDH(co) (green triangles), and NiAl-LDH-IBU(co) 387 
(light blue asterix), and anionic-exchanged (ex) MgAl-LDH-IBU(ex) (red squares) and MgFe-LDH-388 
IBU(ex) (purple crosses). 389 
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 All the LDH-IBU composites tested showed an initial burst release within the first 5 minutes 390 
that corresponds to the release of IBU from the edges and external surfaces of the LDH particles 391 
[31,50]. The initial release is greatest with MgFe-LDH-IBU(co), which may indicate that the majority 392 
of its IBU was associated with the outer surfaces of this LDH. This is supported by the pXRD 393 
analysis that revealed poorer crystallinity compared to the other composites. MgFe-LDH-IBU(ex) 394 
showed limited release, which suggests most of the IBU available for release was relinquished in 395 
the initial burst phase. pXRD of this LDH did not suggest any IBU was intercalated but had adhered 396 
onto the outer surfaces of the LDH. 397 
 A slower release rate of IBU followed the initial burst and corresponds to the phosphate ions 398 
in the solution exchanging with the adsorbed IBU. LDHs are semi-rigid lamellar solids and 399 
demonstrate a reduction in interlayer spacing when larger anions are exchanged with the smaller 400 
anions [31]. As the intercalated IBU is exchanged for phosphate ions at the outer edges the 401 
interlayer space reduces, inhibiting exchange with IBU deeper within the LDH structure. This can 402 
explain the slow and partial release of IBU in anionic-exchanged LDHs as they have more crystalline 403 
layers. Co-precipitated and anionic-exchanged MgAl-LDH-IBU have similar crystallinity, which may 404 
explain their similar release profiles.  405 
It is also likely that differences in the chemical composition and charge density of LDH layers 406 
will affect the strength of interaction with IBU and therefore affect how easily the IBU can be 407 
liberated thereafter [9,33]. Extrapolating this theory would suggest that IBU was held most 408 
strongly within anionic-exchanged composites, especially MgFe-LDH-IBU(ex), and less strongly 409 
within co-precipitated composites. 410 
It is also proposed that H2PO4- reacts with exposed hydroxyl groups of LDHs to produce a 411 
hydroxyphosphate [51]. This is known as a solid state grafting reaction which obstructs IBU release 412 
from deep within the layers due to the strong bonds between phosphate ions and cationic LDH 413 
layers [50,51]. 414 
 The release of IBU from MgAl-LDH-IBU was also studied by Ambrogi et al. [31], who 415 
established modified release of IBU. The release rate of IBU from MgAl-LDH-IBU was found to be 416 
60% over 20 minutes, which is similar to the data presented here showing 54% drug released over 417 
the first 20 minutes. This demonstrates MgAl-LDH can be used as IBU drug carriers for modified 418 
release.  419 
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  420 
4. Conclusion 421 
IBU intercalates into LDHs by interaction between its negatively charged carboxylic acid group 422 
and the cationic surface of the LDHs. Anionic-exchange of IBU onto a formed LDH generally 423 
produces more crystalline and ordered materials compared to co-precipitating the LDH with IBU. 424 
Intercalated IBU is initially released rapidly from the LDHs outer surfaces, then more slowly by ion-425 
exchange with phosphate ions in the dissolution medium. Formation of LDH-IBU composites via 426 
ion exchange generally results in slower, partial, drug release compared to its co-precipitated 427 
counterparts, which may be explained by intensity of LDU and IBU interactions. 428 
The chemical composition of LDHs affects the crystallinity of the overall particle structure, 429 
which affects the intercalation of IBU and its subsequent release profile. Mg2+ and Al3+ ions form 430 
the most crystalline LDHs. The substitution of Mg2+ cations with higher charge-density Ni2+ cations 431 
makes it difficult to synthesise LDH layers. Substitution of Al3+ cation with Fe3+ cation distorts the 432 
layers due to its larger atomic radius. Therefore, Mg2+ and Al3+ ions were found to have the best 433 
charge densities to form the cationic layers of LDHs. 434 
This study demonstrates that MgAl-LDH has the optimal metal composition of LDHs to act as a 435 
host for modifying release of IBU out of the four LDHs synthesised. Further research into the use of 436 
MgAl-LDH as a drug carrier could yield interesting and promising materials for optimising patient 437 
care. 438 
 439 
5. Future perspectives 440 
The arena of drug delivery is vast and ever expanding with novel approaches, materials and 441 
technologies emerging from the research. This is justified by the extensive requirements for 442 
modern drug delivery vehicles to improve patient outcomes, support adherence to medicines, and 443 
reduce adverse effects. There are a large number of promising materials being investigated and 444 
applied to the field, each with their set of desirable physicochemical and biological properties. 445 
Current knowledge of the LDH materials provides an understanding of their chemical diversity and 446 
the adaptability of their physical properties. It is this diversity which is the foundation of their 447 
exploitation in biomedical applications.  448 
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The particle size dependent cellular uptake demonstrated by LDH materials make them 449 
particularly interesting for drug delivery [52]. Further exploration of the biocompatibility, 450 
pharmacokinetics and toxicity of LDH-drug hybrids [53] is required before their true potential is 451 
acknowledged and advances made. The benefits of combining drug molecules with LDHs range 452 
from improved drug solubility and bioavailability to overcoming drug resistance. Thus, utilising 453 
such inorganic materials as novel delivery vehicles provides a platform for not only reducing the 454 
use of animal and petroleum based materials in such applications but provides scope for bettering 455 
the therapeutic effect of the drug molecules themselves.  456 
In addition to delivery of drugs, the application of these low-cost materials extends to other 457 
fields of biomedicine including LDH-polymer scaffolds for improved cell regeneration [12], LDH- 458 
immobilised enzyme biosensors [54] as well as gene delivery vectors [55] further widening the 459 
importance of research into these inorganic layered materials. 460 
 461 
6. Executive Summary 462 
Intercalation of ibuprofen in LDHs 463 
 Adsorption of IBU into LDHs was achieved via co-precipitation and anion exchange. 464 
 Co-precipitation of LDHs with IBU produced a lower yield than without IBU, implying larger 465 
anions may inhibit successful formation of LDH layers. 466 
 The co-precipitation of LDHs with IBU resulted in considerably higher drug intercalation 467 
efficiencies and a stronger adsorption of IBU compared to the anion-exchanged counterparts. 468 
Characterisation of LDHs 469 
 FT-IR spectra and pXRD confirmed the intercalation of IBU within the lamellar structure of 470 
MgAl-LDH and MgFe-LDH. An ordered layered structure for NiAl-LDH and NiFe-LDH was not 471 
formed. 472 
Drug release 473 
 LDH chemical composition and IBU intercalation method also affected the final drug release 474 
behaviour. 475 
 An initial burst release was observed for all LDH-IBU composites within the first 5 minutes that 476 
corresponds to the release of IBU from the edges and external surfaces of the LDH particles 477 
20 
 
 A slower release rate of IBU followed the initial burst and corresponds to the phosphate ions 478 
in the solution exchanging with the adsorbed IBU. 479 
 480 
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